EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective
Abstract
Authors
A Taminato A Barbosa FJB Magro P Federico RNT Prioli S Goldflus CB Migliavaca M Falavigna